Vir Biotechnology, Inc.
NASDAQ:VIR
Overview | Financials
Company Name | Vir Biotechnology, Inc. |
Symbol | VIR |
Currency | USD |
Price | 9.77 |
Market Cap | 1,334,972,800 |
Dividend Yield | 0% |
52-week-range | 7.12 - 13.09 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Marianne De Backer M.B.A., M.Sc., Ph.D. |
Website | https://www.vir.bio |
An error occurred while fetching data.
About Vir Biotechnology, Inc.
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD